research Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review
GLP-1 receptor agonists may cause hair loss, but more research is needed.
Search
for
Sort by
Research
60-90 / 1000+ results 
research Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review
GLP-1 receptor agonists for weight loss may cause hair loss, especially in women.
research Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
GLP-1 agonists may increase the risk of hair loss.
research Dermatologic Implications of GLP-1 Receptor Agonist Medications: A Comprehensive Review
GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.
research Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications
Newer GLP-1 drugs like semaglutide may cause hair loss.
research “From evidence to practice” – Insights from the multidisciplinary team on the optimal integration of GLP‐1 receptor agonists in obesity management services
GLP-1 receptor agonists help with weight loss but need to be combined with other treatments for best results.
research GLP‐1 agonists and hair loss: a call for further investigation
More research is needed to understand if GLP-1 agonists affect hair health.
research 556 α 1 -AR agonist induced piloerection protects against the development of traction alopecia
Phenylephrine may help prevent hair loss from pulling on the hair roots.
research S1 OPIOID RECEPTOR AGONISTS AND SERUM PROSTATE SPECIFIC ANTIGENE LEVEL: IS THERE A ROLE FOR PROSTATE CANCER CONTROL AND CHEMOPREVENTION?
Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.
research The effect of treatment with an LH-RH agonist (Buserelin) on gonadal activity growth and bone maturation in children with central precocious puberty
Buserelin safely and effectively suppresses early puberty, potentially improving final height.
research Long-Term Suppression of Testosterone After Treatment with a Gonadotropin-Releasing Hormone Agonist in a Woman with a Presumed Testosterone Secreting Ovarian Tumor
The treatment successfully lowered testosterone levels and reduced symptoms.
research Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy
The combination therapy reduced hirsutism in women with PCOD and was well-tolerated.
research Efficacy of an agonist ofα-MSH, the palmitoyl tetrapeptide-20, in hair pigmentation
Palmitoyl tetrapeptide-20 may help reduce hair greying and increase melanin production.
research Topical treatment with the bacterium-derived c-Met agonist InlB321/15 accelerates healing in the abrasion wound mouse model
Applying InlB321/15 to wounds sped up healing in mice.
research Reversal of premature hair graying treated with a topical formulation containing α-melanocyte-stimulating hormone agonist (Greyverse Solution 2%)
A woman's premature gray hair turned mostly black again after using Greyverse solution and hair supplements for 5 months.
research Treatment With Cyclohexyl Salicylate, an OR2A4 /7 Agonist, Promotes Hair Growth and the Expansion of Epithelial Progenitor Cells in Human Hair Follicles Ex Vivo
Cyclohexyl salicylate may help hair growth and treat hair loss.
research Prevalence and Predictors of Hair Shedding among GLP-1 Receptor Agonist Users: A Cross-Sectional Study from Saudi Arabia
Hair shedding is common in GLP-1 users, affecting treatment adherence.
research Effects of transient receptor potential (TRP) channel agonists and antagonists on slowly adapting type II mechanoreceptors in the rat sinus hair follicle
TRPA1 and TRPV1 channels don't affect mechanotransduction in rat sinus hair follicles.
research Failure of Topical Estrogen Receptor Agonists and Antagonists to Alter Murine Hair Follicle Cycling
Topical estrogen treatments did not change hair growth in certain mouse strains, questioning previous findings on their role in hair growth control.
research Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
GLP-1RAs, like semaglutide and tirzepatide, may cause hair loss, so patients should be informed and monitored.
research Effects of Glucagon-like Peptide-1 Receptor Agonists on Skin Homeostasis and Skin Aging Processes
GLP-1 RAs may help wound healing but can also cause faster facial aging and skin issues.
research Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database
GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
research Lichen planopilaris treated by the peroxisome proliferator activated receptor-γ agonist pioglitazone: Lack of lasting improvement or cure in the majority of patients
Pioglitazone usually doesn't effectively treat or cure lichen planopilaris.
research Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study
GLP-1 RA medications may be linked to hair loss.
research Minoxidil May be a Partial Agonist of Estrogen Receptor Alpha
Minoxidil might partially activate estrogen receptors, affecting hair growth.
research Inhibition of 5α-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL/6 mice
Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.
research The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
The effect of GLP-1 RAs on erectile function is unclear and needs more research.